For the Treatment of First-Line Metastatic Pancreatic Cancer, Thought-Leaders
are Optimistic About the Potential Efficacy Advantages of Two Emerging Agents
Over Currently Available Therapies
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are
Pivotal Drivers for Prescribing, According to a New Report from Decision
BURLINGTON, Mass., July 8, 2013
BURLINGTON, Mass., July 8, 2013 /PRNewswire/ --Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that the effect on key efficacy endpoints, primarily the effect
of an emerging therapy on overall survival, has the greatest influence on
surveyed U.S. and European oncologists' prescribing decisions for metastatic
pancreatic cancer in the first-line treatment setting. Two novel therapies,
nanoparticle paclitaxel (Celgene/Taiho Pharmaceutical's Abraxane) and
rigosertib (Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals'
Estybon), both in combination with gemcitabine (Eli Lilly's Gemzar, generics),
are set to offer significant efficacy advantages over the current standard of
care, gemcitabine monotherapy. Additionally, nanoparticle paclitaxel and
rigosertib offer advantages in safety and tolerability over FOLFIRINOX*, which
along with the poor performance status of many pancreatic cancer patients, is
the major limitation to FOLFIRINOX's uptake.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )
The Decision Base 2013 report entitled Pancreatic Cancer (First-Line,
Metastatic): What Level of Improvement Will Emerging Therapies Need to Show to
Significantly Impact the Market? finds that surveyed U.S. oncologists would
prescribe nanoparticle paclitaxel/gemcitabine and rigosertib/gemcitabine to a
median 35 percent and 20 percent of their first-line metastatic pancreatic
cancer patients, respectively.
The report also finds that the majority of surveyed managed care organization
(MCO) pharmacy directors are receptive to emerging therapies that offer
improvements in median overall survival (MOS) for the treatment of this
patient population. Key opinion leaders indicate that only
rigosertib/gemcitabine could offer a level of MOS that, according to surveyed
U.S. MCO pharmacy directors, would be necessary for inclusion on MCO
"The treatment for first-line metastatic pancreatic cancer has remained
largely unchanged for the past two decades for the majority of patients," said
Decision Resources Analyst Orestis Mavroudis-Chocholis, Ph.D. "Nanoparticle
paclitaxel's imminent approval in this setting will provide a much-needed
treatment option for patients who are not eligible to receive FOLFIRINOX.
Additionally, based on limited data from an early-stage clinical trial, adding
rigosertib to gemcitabine promises to offer an improvement in MOS, accompanied
with little added toxicity, making this treatment suitable for a broad
proportion of patients and partially addressing key unmet needs in the
treatment of this disease."
*FOLFIRINOX: 5-fluorouracil (5-FU, generics), leucovorin (folinic acid,
generics), irinotecan (Pfizer's Camptosar/Campto, Daiichi Sankyo's Topotecin,
Yakult Honsha's Campto, generics) and oxaliplatin (Sanofi's
Eloxatin/Eloxatine, Yakult Honsha's Elplat, generics).
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.